Letter from COS, CPA and CSPCP re Atropine: Update

(Update: August 2018) Novartis/Alcon will not discontinue the sale of Atropine 1% as they had previously announced. The decision came after consideration of the joint letter that was sent in May 2018 (below).

(May 2018) The Canadian Ophthalmological Society, the Canadian Psychiatric Association, and the CSPCP sent a joint letter to Novartis/Alcon, urging them to reconsider the upcoming discontinuation of Atropine.

View letter here